Document:

Exhibit 10.2

      
        
           

          

          Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted 

          pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be
            competitively 

          harmful if publicly disclosed.

        

      

      

      

      

       

      Execution Version

       

      September 24, 2021

       

      STRICTLY CONFIDENTIAL

      

      

      ReWalk Robotics Ltd.

      Hatnufa Street, Floor 6

      Yokneam Ilit, Israel 2069203

      

      

      Attn: Larry Jasinski, Chief Executive Officer

      

      

      Dear Mr. Jasinski:

       

      This letter agreement (this “Agreement”)

        constitutes the agreement between ReWalk Robotics Ltd. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering of securities of the Company (the “Securities”), including, but not limited to,  restructuring of the outstanding warrants of the Company (a “Warrant Restructuring”),

        during the Term (as hereinafter defined) of this Agreement (each, an “Offering”).  The terms of each Offering and the Securities issued in connection
        therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any
        Securities.  It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and
        to the receipt of all internal approvals of Wainwright in connection with an Offering.  The Company expressly acknowledges and agrees that Wainwright’s involvement in an Offering is strictly on a reasonable best efforts basis and that the
        consummation of an Offering will be subject to, among other things, market conditions.  The execution of this Agreement does not constitute a commitment by Wainwright to purchase the Securities and does not ensure a successful Offering of the
        Securities or the success of Wainwright with respect to securing any other financing on behalf of the Company.  Wainwright may retain other brokers, dealers, agents or underwriters on its behalf in connection with an Offering.

       

      A.          Compensation; Reimbursement.  At the closing of each Offering (each, a “Closing”),

          the Company shall compensate Wainwright as follows:

       

      	

            	1.	
              Cash Fee.  The Company shall pay to Wainwright a cash fee, or
                as to an underwritten Offering an underwriter discount, equal to 7.5% of the aggregate gross proceeds raised in each Offering.

            

       

      	

            	2.	
              Warrant Coverage.  The Company shall issue to Wainwright or
                its designees at each Closing, warrants (the “Wainwright Warrants”) to purchase that number of ordinary shares, par value NIS 0.25 per share (“Ordinary Shares”), of the Company equal to 6.0% of the aggregate number of Ordinary Shares placed in each Offering (and if an Offering includes a
                “greenshoe” or “additional investment” option component, such number of Ordinary Shares underlying such additional option component, with the Wainwright Warrants issuable upon the exercise of such option).  If the Securities included in an
                Offering are convertible, the Wainwright Warrants shall be determined by dividing the gross proceeds raised in such Offering by the Offering Price (as defined hereunder).  The Wainwright Warrants shall have the same terms as the warrants
                issued to investors in the applicable Offering, except that such Wainwright Warrants shall have an exercise price equal to 125% of the offering price per share (or unit, if applicable) in the applicable Offering and if such offering price
                is not available, the market price of the Ordinary Shares on the date an Offering is commenced (such price, the “Offering Price”).  If no warrants
                are issued to investors in an Offering, the Wainwright Warrants shall be in a customary form reasonably acceptable to Wainwright, have a term of five (5) years and an exercise price equal to 125% of the Offering Price.

            

       

      
        
          

      

      
      	

            	3.	
              Expense Allowance.  Out of the proceeds of each Closing, the
                Company also agrees to pay Wainwright (a) a management fee equal to 1.0% of the gross proceeds raised in each Offering; (b) $35,000 for non-accountable expenses (to be reduced to $30,000 for a Warrant Restructuring); (c) up to $90,000 for
                fees and expenses of outside legal counsel and other out-of-pocket expenses for an Offering other than a Warrant Restructuring; plus the additional amount payable by the Company pursuant to Paragraph D.3 hereunder; provided, however, that
                such amount in no way limits or impairs the indemnification and contribution provisions of this Agreement.

            

       

      	

            	4.	
              Tail.  Wainwright shall be entitled to compensation under
                clauses (1) and (2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such financing or capital is provided to the Company by investors whom Wainwright had contacted directly during the Term or introduced to the Company directly during
                the Term, if such Tail Financing is consummated at any time within the 12-month period following the expiration or termination of this Agreement; provided, however, that each of the following transactions shall not be considered as Tail
                Financing: (i) the offer, grant, issuance or sale by the Company of equity or debt securities in financings with a strategic investor or group of strategic investors from China and Japan (including investors and funds located outside of
                China and Japan but whose primary focus is investing in those locations) (ii) in an equity line of credit with (a) [*] and affiliated entities or (b) Aspire Capital Fund, LLC and affiliated entities or (iii) Strategic Investment or
                partnership through Locust Walk Partners or affiliated entities, or in relation to the refinancing of the Company’s outstanding debt to Kreos Capital (Expert Fund) V Limited (“Kreos”) or affiliated entities, (iv) the offer, issuance or sale by the Company of its Ordinary Shares in the at-the-market offering program pursuant to the equity distribution agreement, dated May 9, 2019,
                between the Company and Piper Jaffray & Co. (“Piper”) or any new agreement between the Company and Piper, or (v) the issuance of ordinary shares under the investment agreement, dated March 6, 2018, between the Company and Timwell
                Corporation Limited (“Timwell”) and/or under a new agreement with Timwell or affiliates of Timwell with substantially the same terms (the
                transactions contemplated in sections (i), (ii), (iii), (iv) and (v) above referred to herein as the “Excluded Transactions”).

            

       

      
        2

        
          

      

      	

            	5.	
              Right of First Refusal.  If, from the date hereof until the 12-month anniversary following consummation of each Offering, the Company or any of its subsidiaries (a) decides to finance or refinance any indebtedness
                  using a manager or agent, Wainwright (or any affiliate designated by Wainwright) shall have the right to act as sole book-runner, sole manager, sole placement agent or sole agent with respect to such financing or refinancing; or (b)
                  decides to raise funds by means of a public offering or a private placement of equity, equity-linked or debt securities using an underwriter or placement agent, Wainwright (or any affiliate designated by Wainwright) shall have the right
                  to act as sole book-running manager, sole underwriter or sole placement agent for such financing; provided, however, that Wainwright shall not be entitled to a right of first refusal in connection with the Excluded Transactions. If Wainwright or one of its affiliates decides to accept any such engagement, the agreement governing such engagement will contain, among other things, provisions for
                  customary fees for transactions of similar size and nature and the provisions of this Agreement, including indemnification, which are appropriate to such a transaction.

            

       

      B.          Term and Termination of Engagement; Exclusivity.  The term of
            Wainwright’s exclusive engagement will begin on the date hereof and end sixty (60) days thereafter (the “Initial Term”); provided, however, that if an Offering is consummated within the Initial Term, the term of this Agreement shall be extended by an additional thirty (30) day period (the “Extension Term,” and together with the Initial Term, the “Term”). Notwithstanding anything to the contrary contained herein, the Company
            agrees that the provisions relating to the payment of fees, reimbursement of expenses, right of first refusal, tail, indemnification and contribution, confidentiality, conflicts, independent contractor and waiver of the right to trial by jury
            will survive any termination or expiration of this Agreement.  Notwithstanding anything to the contrary contained herein, the Company has the right to terminate the Agreement for cause in compliance with FINRA Rule 5110(g)(5)(B)(i). The
            exercise of such right of termination for cause eliminates the Company’s obligations with respect to the provisions relating to the tail fees and right of first refusal. Notwithstanding anything to the contrary contained in this Agreement, in
            the event that an Offering pursuant to this Agreement shall not be carried out for any reason whatsoever during the Term, the Company shall be obligated to pay to Wainwright its actual and accountable out-of-pocket expenses related to an
            Offering (including the fees and disbursements of Wainwright’s legal counsel). During Wainwright’s engagement hereunder: (i) the Company will not, and will not permit its representatives to, other than in coordination with Wainwright, contact
            or solicit institutions, corporations or other entities or individuals as potential purchasers of the Securities and (ii) the Company will not pursue any financing transaction which would be in lieu of an Offering, other than the
          Excluded Transactions. Furthermore, the Company agrees that during Wainwright’s engagement hereunder, all inquiries from prospective investors will be referred to
            Wainwright. Additionally, except as set forth hereunder, the Company represents, warrants and covenants that no brokerage or finder’s fees or commissions are or
            will be payable by the Company or any subsidiary of the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other third-party with respect to any Offering.

       

      
        3

        
          

      

      C.          Information; Reliance.  The Company shall furnish, or cause to be furnished, to Wainwright all information requested by Wainwright for the
          purpose of rendering services hereunder and conducting due diligence (all such information being the “Information”).  In addition, the Company agrees to
          make available to Wainwright upon request from time to time the officers, directors, accountants, counsel and other advisors of the Company.  The Company recognizes and confirms that Wainwright (a) will use and rely on the Information, including
          any documents provided to investors in each Offering (the “Offering Documents”) which shall include any Purchase Agreement (as defined hereunder), and on
          information available from generally recognized public sources in performing the services contemplated by this Agreement without having independently verified the same; (b) does not assume responsibility for the accuracy or completeness of the
          Offering Documents or the Information and such other information; and (c) will not make an appraisal of any of the assets or liabilities of the Company.  Upon reasonable request, the Company will meet with Wainwright or its representatives to
          discuss all information relevant for disclosure in the Offering Documents and will cooperate in any investigation undertaken by Wainwright thereof, including any document included or incorporated by reference therein.  At each Offering, at the
          request of Wainwright, the Company shall deliver such legal letters (including, without limitation, negative assurance letters), opinions, comfort letters, officers’ and secretary certificates and good standing certificates, all in form and
          substance satisfactory to Wainwright and its counsel as is customary for such Offering.  Wainwright shall be a third party beneficiary of any representations, warranties, covenants, closing conditions and closing deliverables made by the Company
          in any Offering Documents, including representations, warranties, covenants, closing conditions and closing deliverables made to any investor in an Offering.

       

      D.          Related Agreements.  At each Offering, the Company shall enter into the following additional agreements:

       

      	

            	1.	
              Underwritten Offering.  If an Offering is an underwritten
                Offering, the Company and Wainwright shall enter into a customary underwriting agreement in form and substance satisfactory to Wainwright and its counsel.

            

       

      	

            	2.	
              Best Efforts Offering.  If an Offering is on a best efforts
                basis, the sale of Securities to the investors in the Offering will be evidenced by a purchase agreement (“Purchase Agreement”) between the Company
                and such investors in a form reasonably satisfactory to the Company and Wainwright.  Wainwright shall be a third party beneficiary with respect to the representations, warranties, covenants, closing conditions and closing deliverables
                included in the Purchase Agreement. Prior to the signing of any Purchase Agreement, officers of the Company with responsibility for financial affairs will be available to answer inquiries from prospective investors.

            

       

      	

            	3.	
              Escrow, Settlement and Closing.  If each Offering is not
                settled via delivery versus payment (“DVP”), the Company and Wainwright shall enter into an escrow agreement with a third party escrow agent pursuant
                to which Wainwright’s compensation and expenses shall be paid from the gross proceeds of the Securities sold.  If the Offering is settled in whole or in part via DVP, Wainwright shall arrange for its clearing agent to provide the funds to
                facilitate such settlement; provided, however, if the clearing firm provides the funds in a best efforts offering and subsequent to such delivery an investor fails to provide the necessary funds to the clearing agent for such purchase of
                Securities, Wainwright shall instruct the clearing agent to promptly return any such Securities to the Company and the Company shall promptly return such investor’s purchase price to the clearing agent. The Company shall pay Wainwright
                closing costs, which shall also include the reimbursement of the out-of-pocket cost of the escrow agent or clearing agent, as applicable, which closing costs shall not exceed $15,950.

            

       

      
        4

        
          

      

      	

            	4.	
              FINRA Amendments.  Notwithstanding anything herein to the
                contrary, in the event that Wainwright determines that any of the terms provided for hereunder shall not comply with a FINRA rule, including but not limited to FINRA Rule 5110, then the Company shall agree to amend this Agreement (or
                include such revisions in the final underwriting agreement) in writing upon the request of Wainwright to comply with any such rules; provided that any such amendments shall not provide for terms that are less favorable to the Company than
                are reflected in this Agreement.

            

       

      E.          Confidentiality.  In the event of the consummation or public announcement of any Offering, Wainwright shall have the right to disclose its
          participation in such Offering, including, without limitation, the Offering at its cost of “tombstone” advertisements in financial and other newspapers and journals.

       

      F.          Indemnity.

       

      	

            	1.	
              In connection with the Company’s engagement of Wainwright hereunder, the Company hereby agrees to indemnify and hold harmless Wainwright and its affiliates, and the
                respective controlling persons, directors, officers, members, shareholders, agents and employees of any of the foregoing (collectively the “Indemnified Persons”),

                from and against any and all claims, actions, suits, proceedings (including those of shareholders), damages, liabilities and expenses incurred by any of them (including the reasonable fees and expenses of counsel), as incurred, whether or
                not the Company is a party thereto (collectively a “Claim”), that are (A) related to or arise out of (i) any actions taken or omitted to be taken
                (including any untrue statements made or any statements omitted to be made) by the Company, or (ii) any actions taken or omitted to be taken by any Indemnified Person in connection with the Company’s engagement of Wainwright, or (B)
                otherwise relate to or arise out of Wainwright’s activities on the Company’s behalf under Wainwright’s engagement, and the Company shall reimburse any Indemnified Person for all expenses (including the reasonable fees and expenses of
                counsel) as incurred by such Indemnified Person in connection with investigating, preparing or defending any such claim, action, suit or proceeding, whether or not in connection with pending or threatened litigation in which any Indemnified
                Person is a party.  The Company will not, however, be responsible for any Claim that is finally judicially determined to have resulted from the gross negligence or willful misconduct of such Indemnified Person for such Claim.  The Company
                further agrees that no Indemnified Person shall have any liability to the Company for or in connection with the Company’s engagement of Wainwright except for any Claim incurred by the Company as a result of such Indemnified Person’s gross
                negligence or willful misconduct.

            

       

      
        5

        
          

      

      	

            	2.	
              The Company further agrees that it will not, without the prior written consent of Wainwright, settle, compromise or consent to the entry of any judgment in any
                pending or threatened Claim in respect of which indemnification may be sought hereunder (whether or not any Indemnified Person is an actual or potential party to such Claim), unless such settlement, compromise or consent includes an
                unconditional, irrevocable release of each Indemnified Person from any and all liability arising out of such Claim.

            

       

      	

            	3.	
              Promptly upon receipt by an Indemnified Person of notice of any complaint or the assertion or institution of any Claim with respect to which indemnification is being
                sought hereunder, such Indemnified Person shall notify the Company in writing of such complaint or of such assertion or institution but failure to so notify the Company shall not relieve the Company from any obligation it may have
                hereunder, except and only to the extent such failure results in the forfeiture by the Company of substantial rights and defenses.  If the Company is requested by such Indemnified Person, the Company will assume the defense of such Claim,
                including the employment of counsel for such Indemnified Person and the payment of the fees and expenses of such counsel, provided,
                however, that such counsel shall be satisfactory to the Indemnified Person and provided further that if the legal counsel to such Indemnified Person reasonably determines that having common counsel would present such counsel with a conflict
                of interest or if the defendant in, or target of, any such Claim, includes an Indemnified Person and the Company, and legal counsel to such Indemnified Person reasonably concludes that there may be legal defenses available to it or other
                Indemnified Persons different from or in addition to those available to the Company, such Indemnified Person will employ its own separate counsel (including local counsel, if necessary) to represent or defend him, her or it in any such
                Claim and the Company shall pay the reasonable fees and expenses of such counsel. If such Indemnified Person does not request that the Company assume the defense of such Claim, such Indemnified Person will employ its own separate counsel
                (including local counsel, if necessary) to represent or defend him, her or it in any such Claim and the Company shall pay the reasonable fees and expenses of such counsel. Notwithstanding anything herein to the contrary, if the Company
                fails timely or diligently to defend, contest, or otherwise protect against any Claim, the relevant Indemnified Person shall have the right, but not the obligation, to defend, contest, compromise, settle, assert crossclaims, or
                counterclaims or otherwise protect against the same, and shall be fully indemnified by the Company therefor, including without limitation, for the reasonable fees and expenses of its counsel and all amounts paid as a result of such Claim or
                the compromise or settlement thereof.  In addition, with respect to any Claim in which the Company assumes the defense, the Indemnified Person shall have the right to participate in such Claim and to retain his, her or its own counsel
                therefor at his, her or its own expense.

            

       

      
        6

        
          

      

      	

            	4.	
              The Company agrees that if any indemnity sought by an Indemnified Person hereunder is held by a court to be unavailable for any reason then (whether or not Wainwright
                is the Indemnified Person), the Company and Wainwright shall contribute to the Claim for which such indemnity is held unavailable in such proportion as is appropriate to reflect the relative benefits to the Company, on the one hand, and
                Wainwright on the other, in connection with Wainwright’s engagement referred to above, subject to the limitation that in no event shall the amount of Wainwright’s contribution to such Claim exceed the amount of fees actually received by
                Wainwright from the Company pursuant to Wainwright’s engagement.  The Company hereby agrees that the relative benefits to the Company, on the one hand, and Wainwright on the other, with respect to Wainwright’s engagement shall be deemed to
                be in the same proportion as (a) the total value paid or proposed to be paid or received by the Company pursuant to the applicable Offering (whether or not consummated) for which Wainwright is engaged to render services bears to (b) the fee
                paid or proposed to be paid to Wainwright in connection with such engagement.

            

       

      	

            	5.	
              The Company’s indemnity, reimbursement and contribution obligations under this Agreement (a) shall be in addition to, and shall in no way limit or otherwise adversely
                affect any rights that any Indemnified Person may have at law or at equity and (b) shall be effective whether or not the Company is at fault in any way.

            

       

      G.          Limitation of Engagement to the Company.  The Company acknowledges that Wainwright has been retained only by the Company, that Wainwright is
          providing services hereunder as an independent contractor (and not in any fiduciary or agency capacity) and that the Company’s engagement of Wainwright is not deemed to be on behalf of, and is not intended to confer rights upon, any shareholder,
          owner or partner of the Company or any other person not a party hereto as against Wainwright or any of its affiliates, or any of its or their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities
          Act or Section 20 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), employees or agents.  Unless otherwise expressly agreed in
          writing by Wainwright, no one other than the Company is authorized to rely upon this Agreement or any other statements or conduct of Wainwright, and no one other than the Company is intended to be a beneficiary of this Agreement.  The Company
          acknowledges that any recommendation or advice, written or oral, given by Wainwright to the Company in connection with Wainwright’s engagement is intended solely for the benefit and use of the Company’s management and directors in considering a
          possible Offering, and any such recommendation or advice is not on behalf of, and shall not confer any rights or remedies upon, any other person or be used or relied upon for any other purpose.  Wainwright shall not have the authority to make any
          commitment binding on the Company.  The Company, in its sole discretion, shall have the right to reject any investor introduced to it by Wainwright.

       

      H.          Limitation of Wainwright’s Liability to the Company.  Wainwright and the Company further agree that neither Wainwright nor any of its
          affiliates or any of its or their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents shall have any liability to the Company, its
          security holders or creditors, or any person asserting claims on behalf of or in the right of the Company (whether direct or indirect, in contract, tort, for an act of negligence or otherwise) for any losses, fees, damages, liabilities, costs,
          expenses or equitable relief arising out of or relating to this Agreement or the services rendered hereunder, except for losses, fees, damages, liabilities, costs or expenses that arise out of or are based on any action of or failure to act by
          Wainwright and that are finally judicially determined to have resulted solely from the gross negligence or willful misconduct of Wainwright.

       

      
        7

        
          

      

      I.          Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to
          agreements made and to be fully performed therein.  Any disputes that arise under this Agreement, even after the termination of this Agreement, will be heard only in the state or federal courts located in the City of New York, State of New York. 
          The parties hereto expressly agree to submit themselves to the jurisdiction of the foregoing courts in the City of New York, State of New York.  The parties hereto expressly waive any rights they may have to contest the jurisdiction, venue or
          authority of any court sitting in the City and State of New York.  In the event Wainwright or any Indemnified Person is successful in any action, or suit against the Company, arising out of or relating to this Agreement, the final judgment or
          award entered shall be entitled to have and recover from the Company the costs and expenses incurred in connection therewith, including its reasonable attorneys’ fees.  Any rights to trial by jury with respect to any such action, proceeding or
          suit are hereby waived by Wainwright and the Company.

       

      J.          Notices.  All notices hereunder will be in writing and sent by certified mail, hand delivery, overnight delivery or e-mail, if sent to
          Wainwright, at the address set forth on the first page hereof, e-mail: notices@hcwco.com, Attention: Head of Investment Banking, and if sent to the Company, to the address set forth on the first page hereof, e-mail:  Larry.jasinski@rewalk.com
          Attention:  Chief Executive Officer.  Notices sent by certified mail shall be deemed received five days thereafter, notices sent by hand delivery or overnight delivery shall be deemed received on the date of the relevant written record of
          receipt, notices sent by e-mail shall be deemed received as of the date and time they were sent.

       

      K.          Conflicts.  The Company acknowledges that Wainwright and its affiliates may have and may continue to have investment banking and other
          relationships with parties other than the Company pursuant to which Wainwright may acquire information of interest to the Company.  Wainwright shall have no obligation to disclose such information to the Company or to use such information in
          connection with any contemplated transaction.

       

      L.          Anti-Money Laundering.  To help the United States government fight the funding of terrorism and money laundering, the federal laws of the
          United States require all financial institutions to obtain, verify and record information that identifies each person with whom they do business.  This means Wainwright must ask the Company for certain identifying information, including a
          government-issued identification number (e.g., a U.S. taxpayer identification number) and such other information or documents that Wainwright considers appropriate to verify the Company’s identity, such as certified articles of incorporation, a
          government-issued business license, a partnership agreement or a trust instrument.

       

      M.          Miscellaneous.  The Company represents and warrants that it has all requisite power and authority to enter into and carry out the terms and
          provisions of this Agreement and the execution, delivery and performance of this Agreement does not breach or conflict with any agreement, document or instrument to which it is a party or bound.  This Agreement shall not be modified or amended
          except in writing signed by Wainwright and the Company.  This Agreement shall be binding upon and inure to the benefit of both Wainwright and the Company and their respective assigns, successors, and legal representatives. If any provision of
          this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such provision in any other respect, and the remainder of the Agreement shall remain in full force and effect.  This Agreement may be
          executed in counterparts (including electronic counterparts), each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Signatures to this Agreement transmitted by electronic mail in
          “portable document format” (.pdf) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original
          signature. The undersigned hereby consents to receipt of this Agreement in electronic form and understands and agrees that this Agreement may be signed electronically. In the event that any signature is delivered by electronic mail, or otherwise
          by electronic transmission evidencing an intent to sign this Agreement, such electronic mail or other electronic transmission shall create a valid and binding obligation of the undersigned with the same force and effect as if such signature were
          an original. Execution and delivery of this Agreement by electronic mail or other electronic transmission is legal, valid and binding for all purposes.

       

      *********************

      
        8

        
          

      

      In acknowledgment that the foregoing correctly sets forth the understanding reached by Wainwright and the Company,
        please sign in the space provided below, whereupon this letter shall constitute a binding Agreement as of the date indicated above.

       

      
        	
                 

              	
                
                  Very truly yours,

                   

                  H.C. WAINWRIGHT & CO., LLC

                   

                  By:  /s Edward D. Silvera

                  Name: Edward D. Silvera

                  Title: Chief Operating Officer

                

              

      

      

      Accepted and Agreed:

       

      REWALK ROBOTICS LTD.

       

      By:  /s Lawrence J. Jasinski

      Name: Lawrence J. Jasinski

      Title: Chief Executive Officer

      

    

  

  9Exhibit 10.11

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

 

SECOND
AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT

 

This
Second Amendment to the Exclusive License Agreement (“Second Amendment”) effective as of August 3, 2021 (“Second Amendment
Effective Date”) is by and between: EISAI INC., with its principal office at 100 Tice Blvd., Woodcliff Lake, NJ 07093, United
States of America (“Eisai”) and ALLARITY THERAPEUTICS A/S, with its principal office at Venlighedsvej 1, DK-2970 Hoersholm,
Denmark (“Allarity”) (formerly known as Oncology Venture ApS), with reference to the following:

 

WITNESSETH:

 

WHEREAS,
as of July 6, 2017, the Parties entered into an Exclusive License Agreement, (the “Original Agreement”) relating to the cancer
drug E7449 (now Stenoparib (2X-121)), a PARP inhibitor,

 

WHEREAS,
as of December 11, 2020, the Parties executed a First Amendment to said Exclusive License Agreement, expanding the Field;

 

WHEREAS,
Eisai and Allarity now desire to amend certain provisions of the Original Agreement, in order to (1) postpone the due date of the Extension
Payment (as defined below) by extending the deadline for Allarity’s Successful Completion of its first Phase 2 clinical trial for
Stenoparib; and (2) amend terms related to Eisai’s right of termination of Development.

 

NOW,
THEREFORE, in consideration of the foregoing premises, and the mutual promises and covenants of Parties set forth herein, the Parties
have agreed as follows:

 

	1.	Definitions

 

Capitalized
terms used in this Second Amendment and not defined herein shall have the meanings assigned thereto in the Original Agreement.

 

	2.	Amendments
                                            and Agreements

 

		1)	Section
7.6 of the Original Agreement, “Extension Payment”, is hereby amended and restated in its entirety as follows:

 

Section
7.6 Extension Payment. If Allarity and/or its Affiliates or sublicensees have not achieved Successful Completion of the first
Phase 2 Clinical Trial of the Product prior to December 31, 2022, then, in Allarity’s sole discretion, it may notify Eisai of
its intention to continue Development activities of the Compound. In the event that Eisai and Allarity mutually agree to such
continued Development activities by Allarity, Allarity shall pay a one-time payment to Eisai of [***] U.S. Dollars (the
“Extension Payment”) within thirty (30) days following December 31, 2022. Notwithstanding the foregoing, in the event
that Allarity has not enrolled and dosed at least thirty (30) patients with the first dose of cancer drug E7449 in the ongoing Phase
2 Ovarian Cancer Clinical Trial by July 1, 2022 then the Extension Payment shall become due and payable in full by July 30,
2022.

 

     

     

    

 

		2)	Section
                                            14.2(f)(i) of the Original Agreement, “Eisai Right of Termination for Development”,
                                            is hereby amended and restated in its entirety as follows:

 

Section
14.2(f) Eisai Right of Termination for Development.

 

		(i)	If
                                            Allarity and/or its Affiliates or sublicensees have not achieved Successful Completion of
                                            the first Phase 2 Clinical Trial of the Product prior to December 31, 2022 and Allarity elected
                                            not to pay the Extension Payment pursuant to Section 7.6, Eisai may terminate this Agreement
                                            in its entirety, in its sole discretion, at any time following thirty (30) days from December
                                            31, 2022, on at least one hundred and twenty (120) days prior written notice.

 

	3.	Effect

 

This
Second Amendment shall be effective from the Second Amendment Effective Date.

 

	4.	No
                                            Other Amendments

 

This
Second Amendment shall be deemed to be part of and incorporated into the Original Agreement. Except as expressly set forth in this Second
Amendment, all of the terms and conditions of the Original Agreement shall remain unchanged and are ratified, confirmed in all respects,
and remain in full force and effect.

 

	5.	Counterparts

 

This
Second Amendment may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together
shall be deemed to constitute one and the same instrument. An executed signature page of this Second Amendment delivered by facsimile
transmission or by electronic mail in “portable document format” shall be as effective as an original executed signature
page.

 

[Signature
Page Follows]

 

     

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Second Amendment through their duly authorized representatives and made effective
as of the Second Amendment Effective Date.

 

	Allarity Therapeutics A/S	 	Eisai, Inc.
	 	 	 
	By:	/s/
    James G. Cullem                                        	 	By:	/s/
    Takashi Owa
	Name:	James G. Cullem, J.D.	 	Name:	Takashi Owa
	Title:	Senior V.P., Corporate
    Development	 	Title:	Chief Medicine Creation
    Officer Oncology Business Group Eisai Inc.
		 	 
	Date: 20 August 2021	 	Date: 2021年8月23日

 

[Signature
Page to Second Amendment to Exclusive License Agreement between Allarity and Eisai]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]